Videos

Learn how pharmacists secure access to new therapies with copay cards, BlinkRx pricing, and prior-authorization tips that cut delays.

The panelists examined the practical pathways available to community pharmacists who want to build their menopause expertise, with a strong consensus around the Menopause Society as a foundational starting point, offering position statements, continuing education, an annual meeting boot camp, and a certification pathway open to pharmacists, nurse practitioners, physical therapists, mental health counselors, and physicians alike.

In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, discusses how pharmacists can serve as patient advocates in GLP-1 care and how direct access models may simplify the patient journey while preserving clinical oversight.

In this episode, 'BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma,' the expert oncologists and oncology pharmacists explored the following questions: What is the biological rationale for targeting B-cell maturation antigen (BCMA) in multiple myeloma? What are the different types of BCMA-targeted therapies and what are the Food and Drug Administration (FDA)-approved options? How do the mechanisms of action differ for the 3 different types of BCMA-targeted therapies? What unmet needs in relapsed/refractory multiple myeloma (RRMM) are addressed by BCMA-directed therapies? What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?

Welcome back to another Pharmacy Times Practice Pearls series. In this episode titled, 'Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma,' Ryan Haumschild led the conversation about the following question: What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?

Pharmacy Times interviews Nicole McMullin, regional clinical pharmacist at American Oncology Network, about the oncology pharmacist’s role in outpatient BiTE therapy and the monitoring protocols for identifying and managing CRS and ICANS during step-up dosing.

In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, discusses how data, automation, provider-led programs, and pharmacist support can help improve GLP-1 access, appropriate use, adherence, and patient persistence.

This episode, titled 'Roles, Resources, and Relationships: The Stakeholder Framework Behind Successful Myeloma Care Transitions,' features oncology pharmacists discussing the following critical questions:

In 'When It Works: Best-Case Scenarios and Lessons Learned From Successful Care Transitions in Myeloma,' our panel of experts delve into the following critical question:

Pharmacy Times interviews Nicole McMullin, regional clinical pharmacist at American Oncology Network, on how BiTE therapy is changing care for relapsed/refractory multiple myeloma and how AON developed an all-outpatient step-up dosing model.

In addition to the upcoming Annual Forum in September, New England Institute of Ambulatory Care Pharmacists (NEIAP) provides practical education and networking opportunities to support ambulatory care pharmacists.

Wendy St Peter, PharmD, explains how the new cardio-kidney-metabolic (CKM) syndrome guideline supports pharmacist-led medication management, staging tools, and deprescribing.

Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, discusses the New England Institute for Ambulatory Care Pharmacy (NEIAP) Annual Forum and previews key topics of discussion.

The panelists examined the valuable role caregivers can play in identifying early TD movements, noting that patients often mask symptoms during office visits but may not do so around loved ones, and that caregiver education through accessible resources, such as sponsored videos, can help them recognize subtle signs

Tardive dyskinesia disrupts adherence, caregivers, and costs—learn why inpatient and telehealth visits often miss mild symptoms and what to do.

Deanna Horner, PharmD, BCPS, discusses how payers, employers, and health plans can approach GLP-1 coverage by balancing patient access, affordability, clinical value, and long-term cost considerations.

AZA Allsop, MD, PhD, outlines what REMS-style safety monitoring could look like for psychedelic therapies and why top institutions are investing heavily.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how health systems can evaluate suzetrigine for acute pain pathways while balancing evidence, access, formulary sustainability, and pharmacist-led stewardship.

See how a team-based menopause clinic pairs pharmacists, gynecologists, and pelvic floor therapy to streamline care, screening, and symptom relief.

Learn how pharmacists open symptom-first menopause talks, weigh hormonal vs nonhormonal options, and counter social media myths.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on why effective opioid stewardship in acute pain care must extend beyond prescription reduction to include multimodal analgesia, patient-centered outcomes, and standardized health-system pathways.

Yale's AZA Allsop, MD, PhD, on psychedelics as medicine vs wellness tools, and why naturalistic research settings matter for the field.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how multimodal, individualized care can improve acute pain management for opioid-tolerant patients and those receiving buprenorphine or methadone.

The panelists examined how early recognition of TD allows providers to optimize antipsychotic therapy and minimize or eliminate anticholinergic medications before patients progress to higher-burden treatment options such as clozapine.

In this episode, 'Planning Before the First Dose: Pre-Treatment Transition Strategies for Bispecific Antibody Therapy in Myeloma,' the oncology pharmacists explore the following question: 1. Transition planning needs to begin before the first dose is administered, not after step-up dosing is complete. What does that pre-treatment planning look like at your institution?

Tynosynovial giant cell tumor (TGCT) is a rare, locally aggressive condition that significantly impacts patient quality of life and function, yet many patients wait years for diagnosis and may endure multiple surgeries with higher recurrence rates. In this series, Sasha Watson, PharmD (Sylvester Comprehensive Cancer Center) and Alexis Tandyk, PharmD, BCOP (University of Colorado Health), discuss CSF1R inhibitors, the targeted approach transforming TGCT management. They review the pathophysiology and disease burden context, clinical trial evidence from MOTION and ENLIVEN, strategies for differentiating between CSF1R agents, proactive toxicity management frameworks, and practical steps for building a systematic, pharmacist-led TGCT care model.

Stephen Saklad, Melissa Cloyd, Jamie Kneebusch, and Farah Khorassani discussed the importance of ongoing provider re-education on TD, noting that many clinicians remain unfamiliar with the condition and its presentation, particularly given that effective vesicular monoamine transporter 2 (VMAT2) inhibitor treatments have only been available since 2017.

Welcome back to another Pharmacy Times Practice Pearls series. In this episode, titled "Transitions of Care in Multiple Myeloma: Why Handoffs Remain the Biggest Operational Challenge," Zahra Mahmoudjafari led the conversation about the following question: Transitions of care are the single most consistent operational challenge, outranking efficacy and safety concerns. Why are they difficult, and where are the pain points?

Learn how pharmacists guide AML care, from patient education to mutation-targeted menin inhibitors like revumenib and ziftomenib.

A compliance expert outlines what's next for GLP-1 compounding oversight and how pharmacists can stay audit-ready.